CNS Pharmaceuticals, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | — | $7.6M | $7.2M |
| FY2020 | — | $13.9M | $14.0M |
| FY2021 | — | $6.2M | $5.0M |
| FY2022 | — | $8.1M | $10.1M |
| FY2023 | — | $-4.4M | $548.7K |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | — | $7.6M | $7.2M |
| FY2020 | — | $13.9M | $14.0M |
| FY2021 | — | $6.2M | $5.0M |
| FY2022 | — | $8.1M | $10.1M |
| FY2023 | — | $-4.4M | $548.7K |